![How can Teva buck industry trends for 5% yearly generics growth? Launches--and lots of them | Fierce Pharma How can Teva buck industry trends for 5% yearly generics growth? Launches--and lots of them | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/2016-08/teva2_0.jpg?VersionId=UJI.lugzCtfv67iPUeAzUg2SCIwsODwe)
How can Teva buck industry trends for 5% yearly generics growth? Launches--and lots of them | Fierce Pharma
![一歩間違えば世界金融危機はすぐそこに!3月の米国0.25%利上げをどう考えたらいいのか? | セブツーは、世界各地のファッション&ビューティ情報を多言語で毎日配信するインターナショナル・メディアです。 一歩間違えば世界金融危機はすぐそこに!3月の米国0.25%利上げをどう考えたらいいのか? | セブツーは、世界各地のファッション&ビューティ情報を多言語で毎日配信するインターナショナル・メディアです。](https://www.seventietwo.com/uploads/2023/03/silicon-valley-bank.jpeg)
一歩間違えば世界金融危機はすぐそこに!3月の米国0.25%利上げをどう考えたらいいのか? | セブツーは、世界各地のファッション&ビューティ情報を多言語で毎日配信するインターナショナル・メディアです。
![First Citizens Nearing Deal for Silicon Valley Bank: Bloomberg - 'CoinDesk' News Summary (United States) | BEAMSTART First Citizens Nearing Deal for Silicon Valley Bank: Bloomberg - 'CoinDesk' News Summary (United States) | BEAMSTART](https://www.coindesk.com/resizer/0aOlNTsufTVx5Lv9fJ1Lzx7vNvo=/1200x0/cloudfront-us-east-1.images.arcpublishing.com/coindesk/VO5H3SFKYFHDHJ3XCYT5CFZQFU.png)
First Citizens Nearing Deal for Silicon Valley Bank: Bloomberg - 'CoinDesk' News Summary (United States) | BEAMSTART
![Hey, Pfizer watchers, don't forget Vyndaqel. The heart disease drug's zooming toward blockbuster land | Fierce Pharma Hey, Pfizer watchers, don't forget Vyndaqel. The heart disease drug's zooming toward blockbuster land | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1604500352/VYNDAQEL.jpg/VYNDAQEL.jpg?VersionId=xV9XZMBpWThQlzLQlFHrYyQPJKqp2x6y)
Hey, Pfizer watchers, don't forget Vyndaqel. The heart disease drug's zooming toward blockbuster land | Fierce Pharma
![Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association - Pharma Advancement Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association - Pharma Advancement](https://www.pharmaadvancement.com/wp-content/uploads/Clinical-Trials/12288-teva-company-1000x570.jpg)